Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cisplatin - NanoCarrier

Drug Profile

Cisplatin - NanoCarrier

Alternative Names: Cisplatin micellar nanoparticle; Micelplatin; Nanoplatin; NC-6004

Latest Information Update: 31 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Tokyo
  • Developer NanoCarrier; Orient Europharma
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Bladder cancer; Non-small cell lung cancer
  • Phase I/II Head and neck cancer

Most Recent Events

  • 31 Jan 2019 Phase-I clinical trials in Head and neck cancer (Combination therapy) in European Union (IV) (NanoCarrier pipeline, January 2019)
  • 11 Dec 2018 NanoCarrier and Orient Europharma plan a phase IIa/IIb trial for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater, Late-stage disease) (IV) in USA, in February 2019 , (NCT03771820)
  • 11 Oct 2018 NanoCarrier files an IND application with the US FDA for a phase II trial in Head and neck cancer (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top